FREE MEMBERSHIP

Invitation to join
PCSK9 Education and Research Forum

View the video »

On behalf of the Executive Editorial Board and the Editorial Advisory Board, we warmly invite you to join us in an important new initiative devoted to reducing premature cardiovascular death and disability through a novel therapeutic approach – modulation of hypercholesterolaemia through targeting of PCSK9.

What is PCSK9?
Register to view the video »
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key example of translational medicine. This validated target plays a crucial role in regulating plasma levels of LDL-cholesterol. Within a decade, genetic insights into PCSK9 have driven the development of novel therapies targeting this protein.

Identification of loss-of-function mutations in the PCSK9 gene that are associated with reduced risk for cardiovascular disease have driven the development of novel therapies targeting the PCSK9 protein. Such therapies offer the possibility of fulfilling unmet clinical needs amongst patients at high risk of premature atherosclerotic cardiovascular disease.

Can PCSK9 become a therapeutic target?
Register to view the video »
Clinical studies are investigating the potential of PCSK9 inhibition in key high-risk patient populations, including those who are statin intolerant and those with familial hypercholesterolaemia. PCSK9 provides a real possibility to improve the attainment of LDL-C goals in these patients, ultimately improving patient prognosis.

What is the PCSK9 Education and Research Forum?
The PCSK9 Forum is a worldwide community including clinical investigators and basic researchers, together with a wide horizon of clinical specialists and family practitioners, who wish to understand and explore the potential of PCSK9-targeted therapies to prevent premature cardiovascular mortality and morbidity. Our mission is to communicate evolving knowledge of PCSK9 and to stimulate research into PCSK9 science and therapeutics, with the ultimate goal of enhancing the care pathway for patients at high risk of premature death and disability due to accelerated atherosclerosis and cardiovascular disease. 

What will members gain?
The PCSK9 Forum is an independent, not-for-profit initiative which offers clinicians and scientists worldwide FREE MEMBERSHIP by simply registering at our website.

Registered members will have open access to electronic and multimedia platforms providing real-time reporting of significant developments and news, authoritative analyses and commentaries, and an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences.

Members will receive:

• Regular and timely peer-review updates and analyses of developments in the field.
• Educational tools and resources to enhance understanding of dyslipidaemia and particularly the role of PCSK9 and its relationship to LDL-C and lipoprotein (a) metabolism and circulating levels.
• Invitations to expert-led Forums at Congresses, Symposia and online reviewing the most recent developments from pre-clinical and clinical research.
• Access to research funding to be extended by the Forum in order to drive study of critical questions in dyslipidaemia and atherosclerosis as they relate to PCSK9.

How can I become a member of the Forum?
FREE MEMBERSHIP is available to all qualified researchers and clinicians worldwide.

SIMPLY CLICK HERE TO JOIN NOW

We look forward to future collaboration and interaction with yourself and your colleagues within the context of this exciting, international, not-for-profit initiative.

With best regards,

M John Chapman, PhD, DSc, FESC Editor, PCSK9 Education and Research Forum Research Professor, University of Pierre and Marie Curie, Director Emeritus, INSERM, Past-President, European Atherosclerosis Society, Pitie-Salpetriere University Hospital, Paris, France		Henry N. Ginsberg, MD Editor, PCSK9 Education and Research Forum Irving Professor of Medicine Director, Irving Institute for Clinical and Translational Research College of Physicians and Surgeons Columbia University, New York